Oxford BioMedica break-even still just out of reach
This article was originally published in Scrip
Executive Summary
Oxford BioMedica tried to reassure shareholders in its first-half results announcement that it has enough cash to last until the first quarter of 2013, and that trial results in the meantime could trigger milestone payments from partner Sanofi and deals on other key drugs. However, a number of positive developments are still needed before investors in the company, which carried out the UK's biggest public biotech fundraising this year in January (raising £20 million), will be able to breathe something of a sigh of relief.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.